Nephron LBx Symposium Takeaways – Focus on GH ECLIPSE & ADLT Updates

On Tuesday, Nephron’s Jack Meehan and Sasha Simpson hosted our 2nd Annual Liquid Biopsy Symposium.  The event featured 8 panels digging into the top debates, including participating companies Exact Sciences, Guardant Health, Biological Dynamics and Delfi. In addition, we were joined by leading KOLs and hosted a keynote discussion with former FDA Commissioner Stephen Hahn to debate clinical data, reimbursement and regulatory pathways. The big takeaways for our coverage included updates on Guardant’s ECLIPSE, the pathway for Shield to ADLT status (and $895 Medicare pricing), a discussion on emerging NGS platforms, the future of multi-cancer testing, and much much more.  A full set of takeaways were published to clients this AM.  For more information on Nephron’s research and events, email